Abstract:Introduction: Pulmonary arterial hypertension is a fatal cardiopulmonary disease. Leptin, a neuroendocrine hormone released by adipose tissue, has a complex relationship with cardiovascular diseases, including PAH. Leptin is thought to be an important factor linking metabolic syndrome and cardiovascular disorders. Given the published association between metabolic syndrome and RV dysfunction in PAH, we sought to determine the association between leptin and RV dysfunction. We hypothesized that in PAH-RV, leptin influences metabolic changes via leptin receptors, which can be manipulated by metformin. Methods: Plasma leptin was measured in PAH patients and healthy controls from a published trial of metformin in PAH. Leptin receptor localization was detected in RV from PAH patients, healthy controls, animal models of PH with RV dysfunction before and after metformin treatment, and cultured cardiomyocytes with two different BMPR2 mutants by performing immunohistochemical and cell fractionation studies. Functional studies were conducted in cultured cardiomyocytes to examine the role of leptin and metformin in lipid-driven mitochondrial respiration. Results: In human studies, we found that plasma leptin levels were higher in PAH patients and moderately correlated with higher BMI, but not in healthy controls. Circulating leptin levels were reduced by metformin treatment, and these findings were confirmed in an animal model of RV dysfunction. Leptin receptor expression was increased in PAH-RV cardiomyocytes. In animal models of RV dysfunction and cultured cardiomyocytes with BMPR2 mutation, we found increased expression and membrane localization of the leptin receptor. In cultured cardiomyocytes with BMPR2 mutation, leptin moderately influences palmitate uptake, possibly via CD36, in a mutation-specific manner. Furthermore, in cultured cardiomyocytes, the Seahorse XFe96 Extracellular Flux Analyzer and gene expression data indicate that leptin may not directly influence lipid-driven mitochondrial respiration in BMPR2 mutant cardiomyocytes. However, metformin alone or when supplemented with leptin can improve lipid-driven mitochondrial respiration in BMPR2 mutant cardiomyocytes. The effect of metformin on lipid-driven mitochondrial respiration in cardiomyocytes is BMPR2 mutation-specific. Conclusion: In PAH, increased circulating leptin can influence metabolic signaling in RV cardiomyocytes via the leptin receptor; in particular, it may alter lipid-dependent RV metabolism in combination with metformin in a mutation-specific manner and warrants further investigation.

BMPR2 Mutation and Metabolic Reprogramming in Pulmonary Arterial Hypertension

Genes in pediatric pulmonary arterial hypertension and the most promising BMPR2 gene therapy

Identification of a Novel Mutation in the BMPR2 Gene in a Pulmonary Arterial Hypertension Patient Using Next‐generation Sequencing

BMP Type II Receptor As a Therapeutic Target in Pulmonary Arterial Hypertension.

Pulmonary hypertension induced by right pulmonary artery occlusion: Hemodynamic consequences of BMPR2 mutation

New Mutations and Pathogenesis of Pulmonary Hypertension: Progress and Puzzles in Disease Pathogenesis

Novel Advances in Modifying BMPR2 Signaling in PAH

Autophagy Contributes to BMP Type 2 Receptor Degradation and Development of Pulmonary Arterial Hypertension

Bone morphogenetic protein signalling in pulmonary arterial hypertension: revisiting the BMPRII connection

Adverse effects of BMPR2 suppression in macrophages in animal models of pulmonary hypertension

Molecular genetic framework underlying pulmonary arterial hypertension

Expression of Mutant BMPR-II in Pulmonary Endothelial Cells Promotes Apoptosis and a Release of Factors That Stimulate Proliferation of Pulmonary Arterial Smooth Muscle Cells

A review of BMP and Wnt signaling pathway in the pathogenesis of pulmonary arterial hypertension

Bone morphogenetic protein receptor Ⅱ signaling pathway and pulmonary arterial hypertension:updates and expectations

Metabolic Reprogramming and Redox Signaling in Pulmonary Hypertension

Does BMPR2 Mutation Disrupt Pulmonary Vasculogenesis?

4PBA Restores Signaling of a Cysteine-substituted Mutant BMPR2 Receptor Found in Patients with Pulmonary Arterial Hypertension.

[Metabolic reprogramming in pulmonary hypertension].

Targeting translational read-through of premature termination mutations in <i>BMPR2</i> with PTC124 for pulmonary arterial hypertension

Metabolic reprogramming: A novel metabolic model for pulmonary hypertension

A potential adverse role for leptin and cardiac leptin receptor in the right ventricle in pulmonary arterial hypertension: effect of metformin is BMPR2 mutation-specific